These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30558483)

  • 1. Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6.
    Sixto-López Y; Bello M; Correa-Basurto J
    J Biomol Struct Dyn; 2019 Nov; 37(18):4701-4720. PubMed ID: 30558483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations.
    Sixto-López Y; Bello M; Rodríguez-Fonseca RA; Rosales-Hernández MC; Martínez-Archundia M; Gómez-Vidal JA; Correa-Basurto J
    J Biomol Struct Dyn; 2017 Oct; 35(13):2794-2814. PubMed ID: 27589363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of non-hydroxamate scaffolds against HDAC6 inhibition: A pharmacophore modeling, molecular docking, and molecular dynamics simulation approach.
    Zeb A; Park C; Son M; Rampogu S; Alam SI; Park SJ; Lee KW
    J Bioinform Comput Biol; 2018 Jun; 16(3):1840015. PubMed ID: 29945500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fragment-Based Drug Design of Selective HDAC6 Inhibitors.
    Ruzic D; Djokovic N; Nikolic K
    Methods Mol Biol; 2021; 2266():155-170. PubMed ID: 33759126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
    Uba AI; Yelekçi K
    Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of inhibitors to active-site mutants of CD1, the enigmatic catalytic domain of histone deacetylase 6.
    Osko JD; Christianson DW
    Acta Crystallogr F Struct Biol Commun; 2020 Sep; 76(Pt 9):428-437. PubMed ID: 32880591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
    Porter NJ; Mahendran A; Breslow R; Christianson DW
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
    Rodríguez-Fonseca RA; Sixto-López Y; Fragoso-Vázquez MJ; Flores-Mejía R; Cabrera-Pérez LC; Vázquez-Moctezuma I; Rosales-Hernández MC; Bello M; Martínez-Archundia M; Trujillo-Ferrara JG; Becerra-Martínez E; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(10):1441-1454. PubMed ID: 28044941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Drug Designing Recommends HDAC6 Inhibitors To Attenuate Microtubule-Associated Tau-Pathogenesis.
    Zeb A; Park C; Rampogu S; Son M; Lee G; Lee KW
    ACS Chem Neurosci; 2019 Mar; 10(3):1326-1335. PubMed ID: 30407786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and selective HDAC6 inhibitory activity of N-(4-hydroxycarbamoylbenzyl)-1,2,4,9-tetrahydro-3-thia-9-azafluorenes as novel sulfur analogues of Tubastatin A.
    De Vreese R; Verhaeghe T; Desmet T; D'hooghe M
    Chem Commun (Camb); 2013 May; 49(36):3775-7. PubMed ID: 23538448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity.
    Pflieger M; Sönnichsen M; Horstick-Muche N; Yang J; Schliehe-Diecks J; Schöler A; Borkhardt A; Hamacher A; Kassack MU; Hansen FK; Bhatia S; Kurz T
    ChemMedChem; 2021 Jun; 16(11):1798-1803. PubMed ID: 33629513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC6 inhibitors sensitize non-mesenchymal triple-negative breast cancer cells to cysteine deprivation.
    Alothaim T; Charbonneau M; Tang X
    Sci Rep; 2021 May; 11(1):10956. PubMed ID: 34040090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore-based virtual screening for identification of potential selective inhibitors of human histone deacetylase 6.
    Uba AI; Yelekçi K
    Comput Biol Chem; 2018 Dec; 77():318-330. PubMed ID: 30463049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
    Negmeldin AT; Knoff JR; Pflum MKH
    Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
    Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
    Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
    Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
    J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
    Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
    ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The unraveling of substrate specificity of histone deacetylase 6 domains using acetylome peptide microarrays and peptide libraries.
    Kutil Z; Skultetyova L; Rauh D; Meleshin M; Snajdr I; Novakova Z; Mikesova J; Pavlicek J; Hadzima M; Baranova P; Havlinova B; Majer P; Schutkowski M; Barinka C
    FASEB J; 2019 Mar; 33(3):4035-4045. PubMed ID: 30496698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel inhibitors of histone deacetylase 6: Structure-based virtual screening, molecular dynamics simulation, enzyme inhibition and cell viability assays.
    Uba AI; Hryb M; Singh M; Bui-Linh C; Tran A; Atienza J; Misbah S; Mou X; Wu C
    Life Sci; 2024 Feb; 338():122395. PubMed ID: 38181853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
    Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
    Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.